Ishann Sehgal addresses the eligibility requirements for clinical trials involving renal cell carcinoma (RCC) in this video. He also covers the advancements that ASCO and FCR have made in the treatment of RCC.
According to Ishann, the qualifying standards for RCC clinical research have traditionally been quite stringent. This has the potential to restrict patient involvement and affect the findings of the study. Both the ASCO and the FCR have revised their qualifying requirements in order to accommodate a greater number of patients.
Read The Full Transcript and Watch The Video Here
Ishann discusses the treatment of renal cell carcinoma (RCC) using immune checkpoint inhibitors (ICIs), including recently concluded clinical trials such as CheckMate-9ER and CLEAR. It has been demonstrated that the use of combination therapy that include both ICIs and TKIs can boost progression-free survival as well as overall survival in patients who have advanced RCC.
Ishann stresses the significance of taking the individual patient's characteristics into consideration when determining which RCC therapy options to pursue. She also emphasizes the necessity of continuously analyzing and improving the eligibility criteria for clinical trials in order to maximize patient access and ensure that trial results are applicable to actual patient populations.
For further information, please refer to the poster that is titled "Evaluation of eligibility criteria in contemporary renal cell cancer trials based on ASCO-FCR recommendations."